- Home
- NAKA vs CCCC Comparison
NAKA vs CCCC Comparison
Compare NAKA & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAKA | CCCC |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.8M | 185.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NAKA | CCCC |
|---|---|---|
| Price | $0.26 | $1.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.50 | ★ $7.25 |
| AVG Volume (30 Days) | ★ 4.6M | 874.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,584,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,517.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 71.44 |
| 52 Week Low | $0.25 | $1.09 |
| 52 Week High | $29.50 | $3.64 |
Technical Indicators
Market Signals| Indicator | NAKA | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 33.85 | 47.80 |
| Support Level | $0.26 | $1.79 |
| Resistance Level | $0.33 | $1.97 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 10.01 | 68.56 |
Price Performance
Historical ComparisonAbout NAKA Kindly MD Inc.
Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.